SGLT-2 inhibitors and the risk of hospitalization for community-acquired pneumonia: A population-based cohort study.
SGLT-2 inhibitor
pneumonia
stype 2 diabetes
Journal
Pharmacoepidemiology and drug safety
ISSN: 1099-1557
Titre abrégé: Pharmacoepidemiol Drug Saf
Pays: England
ID NLM: 9208369
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
15
12
2020
accepted:
05
01
2021
pubmed:
12
1
2021
medline:
25
11
2021
entrez:
11
1
2021
Statut:
ppublish
Résumé
Sodium-glucose co-transporter 2 inhibitors (SGLT-2i) have been associated with an increased risk of genitourinary tract infections. Through similar biological mechanisms, they may also increase the risk of community-acquired pneumonia. Our objective was to compare the rate of hospitalization for community-acquired pneumonia (HCAP) with SGLT-2i compared to dipeptidyl peptidase-4 inhibitors (DPP-4i) among patients with type 2 diabetes. We used the United Kingdom's Clinical Practice Research Datalink Gold, linked to hospitalization data, to construct a cohort of patients with type 2 diabetes. Using a time-dependent Cox proportional hazards model, we estimated the adjusted hazard ratio (HR) for HCAP with current use of SGLT-2i versus DPP-4i. Among 29 896 patients, 705 HCAPs occurred over a mean follow-up of 1.7 years (SD: 1.2). Incidence rates for SGLT-2i and DPP-4i users were 6.2 (95% confidence interval [CI]: 3.7, 10.2) and 17.8 (95% CI: 15.3, 20.7) per 1000 person-years, respectively. Current use of SGLT-2i was associated with a decreased risk of HCAP compared to current use of DPP-4i (adjusted HR: 0.48, 95% CI: 0.28, 0.82). However, a comparison of SGLT-2i versus glucagon-like peptide-1 receptor agonists (GLP-1 RA) found no difference in risk of HCAP (adjusted HR: 0.94, 95% CI: 0.44, 1.89). SGLT-2i are associated with a decreased rate of HCAP compared to DPP-4i, but not when compared to GLP-1 RA, among patients with type 2 diabetes.
Substances chimiques
Dipeptidyl-Peptidase IV Inhibitors
0
Hypoglycemic Agents
0
Sodium-Glucose Transporter 2 Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
740-748Subventions
Organisme : CIHR
Pays : Canada
Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. Diabetes Care. 2019;42:S90-S102.
Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347-357.
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-657.
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128.
Wilkinson S, Douglas I, Stirnadel-Farrant H, et al. Changing use of antidiabetic drugs in the UK: trends in prescribing 2000-2017. BMJ Open. 2018;8:e022768.
FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections; 2015 https://www.fda.gov/Drugs/DrugSafety/ucm475463.htm (Accessed September 8, 2017)
Mudaliar S, Polidori D, Zambrowicz B, Henry RR. Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside. Diabetes Care. 2015;38:2344-2353.
Oliveira TL, Candeia-Medeiros N, Cavalcante-Araujo PM, et al. SGLT1 activity in lung alveolar cells of diabetic rats modulates airway surface liquid glucose concentration and bacterial proliferation. Sci Rep. 2016;6:21752.
Gill SK, Hui K, Farne H, et al. Increased airway glucose increases airway bacterial load in hyperglycaemia. Sci Rep. 2016;6:27636.
Baker EH, Baines DL. Airway glucose homeostasis: a new target in the prevention and treatment of pulmonary infection. Chest. 2018;153(2):507-514. https://dx.doi.org/10.1016/j.chest.2017.05.031.
Baker EH, Wood DM, Brennan AL, Clark N, Baines DL, Philips BJ. Hyperglycaemia and pulmonary infection. Proc Nutr Soc. 2006;65:227-235.
Malhotra A, Kudyar S, Gupta AK, Kudyar RP, Malhotra P. Sodium glucose co-transporter inhibitors - a new class of old drugs. Int J Appl Basic Med Res. 2015;5:161-163.
Puckrin R, Saltiel MP, Reynier P, Azoulay A, Yu OHY, Filion KB. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2018;55(5):503-514. https://dx.doi.org/10.1007/s00592-018-1116-0.
Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol. 2015;44:827-836.
Bhaskaran K, Forbes HJ, Douglas I, Leon DA, Smeeth L. Representativeness and optimal use of body mass index (BMI) in the UK Clinical Practice Research Datalink (CPRD). BMJ Open. 2013;3:e003389.
Herbert A, Wijlaars L, Zylbersztejn A, Cromwell D, Hardelid P. Data resource profile: hospital episode statistics admitted patient care (HES APC). Int J Epidemiol. 2017;46:1093.
Padmanabhan S, Carty L, Cameron E, Ghosh RE, Williams R, Strongman H. Approach to record linkage of primary care data from clinical practice research datalink to other health-related patient data: overview and implications. Eur J Epidemiol. 2019;34:91-99.
Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care. 2012;35:2665-2673.
Willemen MJ, Mantel-Teeuwisse AK, Straus SM, Meyboom RH, Egberts TC, Leufkens HG. Use of dipeptidyl Peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase. Diabetes Care. 2011;34:369-374.
Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2008;(2):CD006739. https://dx.doi.org/10.1002/14651858.CD006739.pub2.
Wvan der Zanden R, de Vries F, Lalmohamed A, et al. Use of dipeptidyl-Peptidase-4 inhibitors and the risk of pneumonia: a population-based cohort study. PloS One. 2015;10:e0139367.
Goossen K, Graber S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab. 2012;14:1061-1072.
Faillie JL, Filion KB, Patenaude V, Ernst P, Azoulay L. Dipeptidyl peptidase-4 inhibitors and the risk of community-acquired pneumonia in patients with type 2 diabetes. Diabetes Obes Metab. 2015;17:379-385.
Monami M, Iacomelli I, Marchionni N, Mannucci E. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2010;20:224-235.
Yang W, Cai X, Han X, Ji L. DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2016;32:391-404.
Skull SA, Andrews RM, Byrnes GB, et al. ICD-10 codes are a valid tool for identification of pneumonia in hospitalized patients aged > or = 65 years. Epidemiol Infect. 2008;136:232-240.
Heinzl H, Kaider A, Zlabinger G. Assessing interactions of binary time-dependent covariates with time in cox proportional hazards regression models using cubic spline functions. Stat Med. 1996;15:2589-2601.
Rubin DB. Multiple Imputation for Nonresponse in Surveys. Hoboken, NJ: Wiley; 2004.
Wyss R, Fireman B, Rassen JA, Schneeweiss S. Erratum: high-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2018;29:e63-e64.
Identifier: NCT04350593. Dapagliflozin in Respiratory Failure in Patients With COVID-19 (DARE-19). National Library of Medicine (US), 2020. Retrieved from https://clinicaltrials.gov/ct2/show/NCT04350593 (Accessed April 23, 2020)
Rogliani P, Matera MG, Calzetta L, et al. Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. Respir Med. 2019;154:86-92.
Khan F, Mat A, Hogan AE, et al. Preliminary asthma-related outcomes following glucagon-like peptide 1 agonist therapy. QJM: Int J Med. 2017;110:853-854.
Nguyen D-V, Linderholm A, Haczku A, Kenyon N. Obesity-related, metabolic asthma: a new role for glucagon-like peptide 1 agonists. Lancet Respir Med. 2017;5:162-164.
Monda VM, Porcellati F, Strollo F, Gentile S. ACE2 and SARS-CoV-2 infection: might GLP-1 receptor agonists play a role? Diabetes Ther. 2020;11:1909-1914.
Ou X, O'Leary HA, Broxmeyer HE. Implications of DPP4 modification of proteins that regulate stem/progenitor and more mature cell types. Blood. 2013;122:161-169.
Reinhold D, Biton A, Goihl A, et al. Dual inhibition of dipeptidyl peptidase IV and aminopeptidase N suppresses inflammatory immune responses. Ann NY Acad Sci. 2007;1110:402-409.
Steinbrecher A, Reinhold D, Quigley L, et al. Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-beta 1 secretion in vivo. J Immunol. 2001;166:2041-2048.
Morieri ML, Bonora BM, Longato E, et al. Exposure to dipeptidyl-peptidase 4 inhibitors and the risk of pneumonia among people with type 2 diabetes: retrospective cohort study and meta-analysis. Diabetes Obes Metab. 2020;22:1925-1934.
McCoy RGDHJ, Sangaralingham L, Ross JS, Karaca-Mandic P, Montori VM. Adoption of new glucose-lowering medications in the U.S.-the case of SGLT2 inhibitors: nationwide cohort study. Diabetes Technol Ther. 2019;21:702-712.
Cobo A, Vázquez LA, Reviriego J, Rodríguez-Mañas L. Impact of frailty in older patients with diabetes mellitus: an overview. Endocrinol Nutrición (English Edition). 2016;63:291-303.
Kornum JB, Thomsen RW, Riis A, Lervang HH, Schonheyder HC, Sorensen HT. Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. Diabetes Care. 2008;31:1541-1545.
Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol. 2007;167:492-499.
Millett ERC, Quint JK, De Stavola BL, Smeeth L, Thomas SL. Improved incidence estimates from linked vs. stand-alone electronic health records. J Clin Epidemiol. 2016;75:66-69.
Wright FL, Green J, Canoy D, et al. Vascular disease in women: comparison of diagnoses in hospital episode statistics and general practice records in England. BMC Med Res Methodol. 2012;12:161.